DOSE ESCALATION OF NEXT GENERATION ANTI-CTLA-4 ANTIBODY ONC-392 IN COMBINATION WITH FIXED DOSE OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Hu-Lieskovan, Siwen [1 ]
He, Kai [2 ]
Tang, Mei [3 ]
Chen, Dan [4 ]
Liu, Yang [4 ]
Zheng, Pan [4 ]
Li, Tianhong [5 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA
[3] Greater Baltimore Med Ctr, Baltimore, MD USA
[4] OncoC4 Inc, Rockville, MD USA
[5] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页码：A622 / A622
页数：1
相关论文
共 50 条
  • [21] A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors
    Amarantidis, K.
    Houhouli, K.
    Papatheodorou, K.
    Miloussis, A.
    Matthaios, D.
    Chatzaki, E.
    Lyrantzopoulos, N.
    Tsaroucha, A.
    Tentes, A.
    Kakolyris, S.
    ONCOLOGY RESEARCH, 2006, 16 (06) : 281 - 287
  • [22] IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
    Wang, Shusen
    Zhang, Qingyuan
    Gao, Quanli
    Wu, Shikai
    Li, Enxiao
    Li, Zhi-hua
    Liu, Ziquan
    Zhao, Xiwen
    Gao, Siman
    Lu, Qiying
    Tian, Wenzhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
    Wang, Shusen
    Zheng, Qiufan
    Gao, Quanli
    Zhang, Qingyuan
    Wu, Shikai
    Li, Zhihua
    Li, Enxiao
    Lu, Qiying
    Gan, Frank
    Tian, Wenzhi
    CANCER RESEARCH, 2024, 84 (07)
  • [24] A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors
    Amarantidis, Kyriakos
    Xenidis, Nikolaos
    Chelis, Leonidas
    Chiotis, Anestis
    Tentes, Apostolos
    Chatzaki, Ekaterini
    Kortsaris, Alexandros
    Polychronidis, A.
    Karakitsos, Petros
    Kakolyris, Stylianos
    ACTA ONCOLOGICA, 2010, 49 (02) : 245 - 251
  • [25] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
    Li, Daneng
    Sharma, Sunil
    She, Kristine
    Li, Wenda
    Li, Ai
    Zheng, Songmao
    Liu, Guizhong
    Ndukwo, Ogon
    Hu-Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    Patel, Manish R.
    CANCER RESEARCH, 2023, 83 (08)
  • [26] AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
    Frentzas, Sophia
    Kao, Steven
    Gao, Rang
    Zheng, Hao
    Rizwan, Ahsan
    Budha, Nageshwar
    Pedroza, Luz de la Hoz
    Tan, Wei
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [27] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
    Bendell, Johanna C.
    Bedard, Philippe
    Bang, Yung-Jue
    LoRusso, Patricia
    Hodi, Stephen
    Gordon, Michael
    D'Angelo, Sandra
    Desai, Jayesh
    Garralda, Elena
    Italiano, Antoine
    Myung-Ju Ahn
    Cervantes, Andres
    Wainberg, Zev
    Calvo, Emiliano
    Gil-Martin, Marta
    Martinez-Garcia, Maria
    Bahleda, Rastilav
    Cassier, Philippe
    Delord, Jean-Pierre
    Prawira, Amy
    Melero, Ignacio
    Emens, Leisha
    Romano, Emanuela
    Miller, Karen
    Hsieh, Robert W.
    Xue, Cloris
    Morrissey, Kari
    Twomey, Patrick
    Gash, Kelly
    Patil, Namrata S.
    Grogan, Jane
    Meng, Raymond
    Cho, Byoung
    Kim, Tae Won
    CANCER RESEARCH, 2020, 80 (16)
  • [28] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [29] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [30] Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
    Papadatos-Pastos, Dionysis
    Yuan, Wei
    Pal, Abhijit
    Crespo, Mateus
    Ferreira, Ana
    Gurel, Bora
    Prout, Toby
    Ameratunga, Malaka
    Chenard-Poirier, Maxime
    Curcean, Andra
    Bertan, Claudia
    Baker, Chloe
    Miranda, Susana
    Masrour, Nahal
    Chen, Wentin
    Pereira, Rita
    Figueiredo, Ines
    Morilla, Ricardo
    Jenkins, Ben
    Zachariou, Anna
    Riisnaes, Ruth
    Parmar, Mona
    Turner, Alison
    Carreira, Suzanne
    Yap, Christina
    Brown, Robert
    Tunariu, Nina
    Banerji, Udai
    Lopez, Juanita
    de Bono, Johann
    Minchom, Anna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
12345